| Basics |
uniQure N.V. Ordinary Shares
uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
|
| IPO Date: |
March 1, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.89B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.65 | 2.91%
|
| Avg Daily Range (30 D): |
$2.04 | 4.51%
|
| Avg Daily Range (90 D): |
$0.89 | 2.85%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.59M |
| Avg Daily Volume (30 D): |
5.19M |
| Avg Daily Volume (90 D): |
2.42M |
| Trade Size |
| Avg Trade Size (Sh.): |
92 |
| Avg Trade Size (Sh.) (30 D): |
87 |
| Avg Trade Size (Sh.) (90 D): |
83 |
| Institutional Trades |
| Total Inst.Trades: |
2,861 |
| Avg Inst. Trade: |
$1.62M |
| Avg Inst. Trade (30 D): |
$1.9M |
| Avg Inst. Trade (90 D): |
$1.79M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.9M |
| Avg Closing Trade (30 D): |
$6.18M |
| Avg Closing Trade (90 D): |
$3.31M |
| Avg Closing Volume: |
94.7K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$-.69
|
$-.82
|
|
Diluted EPS
|
|
$-.69
|
$-.82
|
|
Revenue
|
$
|
$ 5.26M
|
$ 1.57M
|
|
Gross Profit
|
$
|
$ 4.61M
|
$ 1.37M
|
|
Net Income / Loss
|
$
|
$ -37.72M
|
$ -43.64M
|
|
Operating Income / Loss
|
$
|
$ -43.87M
|
$ -39.33M
|
|
Cost of Revenue
|
$
|
$ .66M
|
$ .2M
|
|
Net Cash Flow
|
$
|
$ 36.61M
|
$ 58.33M
|
|
PE Ratio
|
|
|
|
|
|
|
